Compare QUALCOMM, Inc. (QCOM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? QUALCOMM, Inc. trades at $177.24 (market cap $182.87B), while Vertex Pharmaceuticals Incorporated trades at $472.52 (market cap $122.33B). The key difference: QUALCOMM, Inc. is the larger of the two by market cap, and QUALCOMM, Inc. pays a 2.12% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| QCOM | VRTX | |
|---|---|---|
Market Cap | $182.87B | $122.33B |
Sector | Technology | Health |
52-Week High | $251.10 | $529.59 |
52-Week Low | $124.07 | $366.54 |
Enterprise Value | $188.34B | $117.07B |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $170.32, down 0.85% with bearish technical signals despite recent earnings beats. The stock shows strong fundamentals with 22.31% net margins and 29.27% ROE, though facing margin pressures and smartphone market headwinds. Recent news highlights AI diversification efforts through automotive and data center markets, with CEO Cristiano Amon projecting 'multiple billions' in data center revenue ahead.
Outlook remains mixed with 42.65% analyst buy ratings and $228.22 consensus target suggesting 34% upside, but technical weakness and competitive threats from Nvidia's PC chip entry create near-term uncertainty. Key risks include smartphone demand softness and margin compression, while AI expansion provides long-term growth potential.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
